Company Profile

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It is engaged in the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long lasting benefits to patients through a biomarker-driven approach. Its pipeline is focused on product candidates to address PD-(L)1-inhibitor resistant and PD-(L)1 inhibitor sensitive tumors. Its program, JTX-8064, is a tumor-associated macrophage candidate from its Translational Science platform. JTX-8064 is a monoclonal antibody that binds to Leukocyte Immunoglobulin Like Receptor B2, (LILRB2), which is a cell surface receptor expressed on macrophages and other myeloid cells. JTX-1484 is a monoclonal antibody designed to block human Leukocyte Immunoglobulin Like Receptor B4, (LILRB4) on various myeloid cells. Its product candidate, vopratelimab, is a monoclonal antibody that binds to and activates T cell CO-Stimulator (ICOS). It also develops JTX-1484 and JTX-2134 product candidates.

Employees

141

Sector

Biotechnology & Medical Research

More about the company

23-08-23	Graphite Bio, Inc. Announces Executive Changes	CI
23-05-04	Jounce Therapeutics, Inc. Announces Board Changes	CI
23-05-04	Jounce Therapeutics, Inc.(NasdaqGS:JNCE) dropped from NASDAQ Composite Index	CI
23-05-04	Jounce Therapeutics, Inc.(NasdaqGS:JNCE) dropped from S&P Global BMI Index	CI
23-05-04	Jounce Therapeutics, Inc.(NasdaqGS:JNCE) dropped from S&P TMI Index	CI
23-05-02	Concentra Biosciences, LLC completed the acquisition of Jounce Therapeutics, Inc. from Tang Capital Management, LLC and others.	CI
23-04-03	Redx confirms Jounce deal lapses, Tirupati seals deal	AN
23-04-03	Redx Pharma Shares Fall 5% as Merger With Jounce Therapeutics Fails	MT
23-03-30	Jounce Therapeutics, Inc. Expects Resignation of Elizabeth Trehu as Chief Medical Officer	CI
23-03-27	Sector Update: Health Care Stocks Rise in Late Trading	MT
23-03-27	European Stock Markets Close Higher Monday as First Citizens BancShares' Planned Acquisition of Silicon Valley Bank Assets, Deposits Eases Banking Crisis Fears	MT
23-03-27	Piper Sandler Downgrades Jounce Therapeutics to Neutral From Overweight, Adjusts Price Target to $1.85 From $5	MT
23-03-27	Jounce dumps Redx Pharma for acquisition by Concentra; to cut 84% of jobs	RE

23-03-27	Piper Sandler Downgrades Jounce Therapeutics to Neutral From Overweight, Adjusts Price Target to $1.85 From $5	MT
23-02-24	SMBC Nikko Downgrades Jounce Therapeutics to Neutral From Outperform	MT
23-02-23	Raymond James Downgrades Jounce Therapeutics to Market Perform From Outperform	MT
23-01-03	Piper Sandler Adjusts Price Target on Jounce Therapeutics to $5 From $6, Maintains Overweight Rating	MT
22-08-30	Raymond James Lowers Price Target for Jounce Therapeutics to $16 From $20, Maintains Buy Rating	MT

23-05-04	JOUNCE THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year (form 8-K)	AQ
23-05-03	Jounce Therapeutics Announces Closing of Tender Offer	AQ
23-04-03	Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc	AQ
23-03-30	JOUNCE THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)	AQ
23-03-27	Jounce Therapeutics : NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OF SUCH JURISDICTION - Form 8-K	PU

22-12-29	MORNING BRIEFING - Deutschland/Europa
22-12-29	MORNING BRIEFING - USA/Asien
22-12-28	MÄRKTE USA/Schwach - Zins- und Inflationssorgen drücken Kurse
22-12-28	Wall Street lager gesloten
22-12-28	Wall Street koerst af op lager slot

Manager	Title	Age	Since
Kevin Tang CEO	Chief Executive Officer	59	-
Michael Hearne DFI	Director of Finance/CFO	-	-
Eric Laub IRC	Investor Relations Contact	-	2021-08-31

Jounce Therapeutics, Inc. Stock

Stocks

JNCE

US4811161011

Biotechnology & Medical Research

Latest news: Jounce Therapeutics, Inc.

Analysts' recommendations: Jounce Therapeutics, Inc.

Press Releases: Jounce Therapeutics, Inc.

News in other languages: Jounce Therapeutics, Inc.

Quotes and Performance

Managers and Directors: Jounce Therapeutics, Inc.

Latest insider transactions

Bio Therapeutic Drugs

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
5/3/23	Luis Diaz	Issuer sale	Director	104,363	0.2002%
5/3/23	Robert Iannone	Issuer sale	Director	74,950	0.1437%
5/3/23	Kim Drapkin	Tender	Chairperson	652,288	1.2510%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
JOUNCE THERAPEUTICS, INC.	-2.59%	-.--%	-	-	98.96M
WUXI APPTEC CO., LTD.	-6.60%	-8.56%	+49.38%	+63.51%	65B
LONZA GROUP AG	+0.03%	+5.56%	+9.10%	+69.05%	51.2B
ARGENX SE	-4.09%	-0.11%	+2.22%	+53.15%	51.19B
IQVIA HOLDINGS INC.	-1.53%	+2.70%	+30.48%	+34.12%	43.93B
BEONE MEDICINES AG	-1.34%	+4.12%	+16.64%	+115.13%	41.96B
REVOLUTION MEDICINES, INC.	-5.97%	-6.22%	+228.95%	+454.22%	38.14B
CELLTRION, INC.	+6.53%	+8.02%	+16.40%	+53.41%	33.24B
WUXI BIOLOGICS (CAYMAN) INC.	-0.90%	-10.49%	+37.09%	-3.70%	25.2B
GENMAB A/S	-1.07%	+2.33%	+19.43%	+9.98%	22.5B
Average	-1.75%	-0.35%	+45.52%	+94.32%	41.37B
Weighted average by Cap.	-2.20%	-0.50%	+44.25%	+96.53%